Literature DB >> 23344935

Beyond the ligand-binding pocket: targeting alternate sites in nuclear receptors.

Laura Caboni1, David G Lloyd.   

Abstract

Nuclear receptors (NRs) are a family of ligand-modulated transcription factors with significant therapeutic relevance from metabolic disorders and inflammation to cancer, neurodegenerative, and psychiatric disorders. Drug discovery efforts are typically concentrated on modulating the natural ligand action within the ligand-binding pocket (LBP) in the C-terminal ligand-binding domain (LBD). Drawbacks of LBP-based strategies include physiological alterations due to disruption of ligand binding and difficulties in achieving tissue specificity. Furthermore, the lack of a "pure" and predictable mechanism of action predisposes such intervention toward drug resistance. Recent outstanding progress in our understanding of NR biology has shifted the focus of drug discovery efforts from inside to outside the LBP, affording consideration to the interaction between NRs and coactivator proteins, the interaction between NRs and DNA and the NRs' ligand-independent functions. This review encompasses such currently available NR non-LBP-based interventions and their potential application in therapy or as specific tools to probe NR biology.
© 2012 Wiley Periodicals, Inc.

Entities:  

Keywords:  alternative site; non-LBP; nuclear receptor

Mesh:

Substances:

Year:  2012        PMID: 23344935     DOI: 10.1002/med.21275

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  30 in total

Review 1.  Steroid receptor/coactivator binding inhibitors: An update.

Authors:  Kornelia J Skowron; Kenneth Booker; Changfeng Cheng; Simone Creed; Brian P David; Phillip R Lazzara; Amy Lian; Zamia Siddiqui; Thomas E Speltz; Terry W Moore
Journal:  Mol Cell Endocrinol       Date:  2019-06-01       Impact factor: 4.102

2.  Modification of the Orthosteric PPARγ Covalent Antagonist Scaffold Yields an Improved Dual-Site Allosteric Inhibitor.

Authors:  Richard Brust; Hua Lin; Jakob Fuhrmann; Alice Asteian; Theodore M Kamenecka; Douglas J Kojetin
Journal:  ACS Chem Biol       Date:  2017-02-16       Impact factor: 5.100

3.  Stapled Peptides with γ-Methylated Hydrocarbon Chains for the Estrogen Receptor/Coactivator Interaction.

Authors:  Thomas E Speltz; Sean W Fanning; Christopher G Mayne; Colin Fowler; Emad Tajkhorshid; Geoffrey L Greene; Terry W Moore
Journal:  Angew Chem Int Ed Engl       Date:  2016-03-01       Impact factor: 15.336

4.  A Cell-Permeable Stapled Peptide Inhibitor of the Estrogen Receptor/Coactivator Interaction.

Authors:  Thomas E Speltz; Jeanne M Danes; Joshua D Stender; Jonna Frasor; Terry W Moore
Journal:  ACS Chem Biol       Date:  2018-01-24       Impact factor: 5.100

Review 5.  Ubiquitylation of nuclear receptors: new linkages and therapeutic implications.

Authors:  Kyle T Helzer; Christopher Hooper; Shigeki Miyamoto; Elaine T Alarid
Journal:  J Mol Endocrinol       Date:  2015-05-05       Impact factor: 5.098

Review 6.  Regulation of the nongenomic actions of retinoid X receptor-α by targeting the coregulator-binding sites.

Authors:  Xiao-kun Zhang; Ying Su; Liqun Chen; Fan Chen; Jie Liu; Hu Zhou
Journal:  Acta Pharmacol Sin       Date:  2014-12-01       Impact factor: 6.150

7.  Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif.

Authors:  Katja Jehle; Laura Cato; Antje Neeb; Claudia Muhle-Goll; Nicole Jung; Emmanuel W Smith; Victor Buzon; Laia R Carbó; Eva Estébanez-Perpiñá; Katja Schmitz; Ljiljana Fruk; Burkhard Luy; Yu Chen; Marc B Cox; Stefan Bräse; Myles Brown; Andrew C B Cato
Journal:  J Biol Chem       Date:  2014-02-12       Impact factor: 5.157

Review 8.  Targeting truncated RXRα for cancer therapy.

Authors:  Xiaokun Zhang; Hu Zhou; Ying Su
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2015-10-21       Impact factor: 3.848

9.  4,4'-Unsymmetrically substituted 3,3'-biphenyl alpha helical proteomimetics as potential coactivator binding inhibitors.

Authors:  Patrick T Weiser; Ching-Yi Chang; Donald P McDonnell; Robert N Hanson
Journal:  Bioorg Med Chem       Date:  2013-11-08       Impact factor: 3.641

10.  Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer.

Authors:  Kush Dalal; Mani Roshan-Moniri; Aishwariya Sharma; Huifang Li; Fuqiang Ban; Mohamed Hessein; Michael Hsing; Kriti Singh; Eric LeBlanc; Scott Dehm; Emma S Tomlinson Guns; Artem Cherkasov; Paul S Rennie
Journal:  J Biol Chem       Date:  2014-08-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.